CN110267954A - 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 - Google Patents
苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 Download PDFInfo
- Publication number
- CN110267954A CN110267954A CN201880010505.2A CN201880010505A CN110267954A CN 110267954 A CN110267954 A CN 110267954A CN 201880010505 A CN201880010505 A CN 201880010505A CN 110267954 A CN110267954 A CN 110267954A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- alkoxy
- group
- halogenated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
本发明涉及N‑(3‑氨基苯基)丙烯酰胺取代的1,2‑二氢吡咯并[3,4‑c]吡啶/嘧啶‑3‑酮衍生物、其制法与医药上的用途。具体地,本发明公开了式(II)化合物或其药学上可接受的盐、立体异构体、溶剂化物或前药,及其制备方法和应用,式中各基团的定义详见说明书和权利要求书。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710897909 | 2017-09-28 | ||
CN2017108979095 | 2017-09-28 | ||
PCT/CN2018/098479 WO2019062328A1 (zh) | 2017-09-28 | 2018-08-03 | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110267954A true CN110267954A (zh) | 2019-09-20 |
CN110267954B CN110267954B (zh) | 2022-05-10 |
Family
ID=65900477
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880010483.XA Active CN110366553B (zh) | 2017-09-28 | 2018-08-03 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
CN201880010505.2A Active CN110267954B (zh) | 2017-09-28 | 2018-08-03 | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
CN202210278145.2A Active CN114478544B (zh) | 2017-09-28 | 2018-08-03 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880010483.XA Active CN110366553B (zh) | 2017-09-28 | 2018-08-03 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210278145.2A Active CN114478544B (zh) | 2017-09-28 | 2018-08-03 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11174254B2 (zh) |
EP (1) | EP3689871B1 (zh) |
JP (1) | JP6922085B2 (zh) |
CN (3) | CN110366553B (zh) |
AU (1) | AU2018342342B2 (zh) |
CA (1) | CA3077238C (zh) |
DK (1) | DK3689871T3 (zh) |
SG (1) | SG11202002767RA (zh) |
WO (2) | WO2019062329A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113061137A (zh) * | 2021-04-02 | 2021-07-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
CA3109765A1 (en) * | 2019-03-18 | 2020-09-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof |
WO2022048551A1 (zh) * | 2020-09-01 | 2022-03-10 | 上海海雁医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102753548A (zh) * | 2009-12-23 | 2012-10-24 | 武田药品工业株式会社 | 作为syk抑制剂的稠合的杂芳族吡咯烷酮 |
WO2017075394A1 (en) * | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
JP6026525B2 (ja) * | 2011-06-22 | 2016-11-16 | 武田薬品工業株式会社 | 置換6−アザ−イソインドリン−1−オン誘導体 |
WO2015048662A2 (en) * | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2015061247A2 (en) * | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
WO2015131080A1 (en) * | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2015158310A1 (zh) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
CN105777756B (zh) * | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
DK3236943T3 (da) * | 2014-12-24 | 2023-04-11 | Principia Biopharma Inc | Sammensætninger til ileo-jejunal lægemiddeladministration |
CN107021963A (zh) * | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
-
2018
- 2018-08-03 CN CN201880010483.XA patent/CN110366553B/zh active Active
- 2018-08-03 WO PCT/CN2018/098481 patent/WO2019062329A1/zh unknown
- 2018-08-03 CA CA3077238A patent/CA3077238C/en active Active
- 2018-08-03 SG SG11202002767RA patent/SG11202002767RA/en unknown
- 2018-08-03 JP JP2020517534A patent/JP6922085B2/ja active Active
- 2018-08-03 WO PCT/CN2018/098479 patent/WO2019062328A1/zh active Application Filing
- 2018-08-03 AU AU2018342342A patent/AU2018342342B2/en not_active Ceased
- 2018-08-03 CN CN201880010505.2A patent/CN110267954B/zh active Active
- 2018-08-03 US US16/486,110 patent/US11174254B2/en active Active
- 2018-08-03 CN CN202210278145.2A patent/CN114478544B/zh active Active
- 2018-08-03 DK DK18862262.5T patent/DK3689871T3/da active
- 2018-08-03 EP EP18862262.5A patent/EP3689871B1/en active Active
-
2020
- 2020-03-27 US US16/833,467 patent/US11155546B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102753548A (zh) * | 2009-12-23 | 2012-10-24 | 武田药品工业株式会社 | 作为syk抑制剂的稠合的杂芳族吡咯烷酮 |
WO2017075394A1 (en) * | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113061137A (zh) * | 2021-04-02 | 2021-07-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
Also Published As
Publication number | Publication date |
---|---|
US11155546B2 (en) | 2021-10-26 |
CN114478544B (zh) | 2023-06-16 |
EP3689871A1 (en) | 2020-08-05 |
JP6922085B2 (ja) | 2021-08-18 |
AU2018342342B2 (en) | 2021-01-07 |
JP2020535170A (ja) | 2020-12-03 |
US20200223846A1 (en) | 2020-07-16 |
SG11202002767RA (en) | 2020-04-29 |
CN110366553B (zh) | 2022-04-15 |
EP3689871A4 (en) | 2020-08-05 |
WO2019062328A1 (zh) | 2019-04-04 |
DK3689871T3 (da) | 2021-12-06 |
CN110267954B (zh) | 2022-05-10 |
US11174254B2 (en) | 2021-11-16 |
EP3689871B1 (en) | 2021-09-29 |
WO2019062329A1 (zh) | 2019-04-04 |
AU2018342342A1 (en) | 2020-04-16 |
CN114478544A (zh) | 2022-05-13 |
US20200048248A1 (en) | 2020-02-13 |
CA3077238A1 (en) | 2019-04-04 |
CN110366553A (zh) | 2019-10-22 |
CA3077238C (en) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103038233B (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
CN105814054B (zh) | 作为tnf活性调节剂的稠合咪唑和吡唑衍生物 | |
CN105143206B (zh) | 用于治疗癌症的嘧啶-2,4-二胺衍生物 | |
CN110267954A (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 | |
US8822514B2 (en) | Multi-cyclic compounds and methods of use | |
JP2010523639A (ja) | 医薬化合物 | |
CN107072985A (zh) | 治疗性抑制化合物 | |
KR20130122778A (ko) | FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체 | |
CN101821255A (zh) | 作为pi3k抑制剂的2-吗啉-4-基-嘧啶类化合物 | |
CN105315285A (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
CN102388055A (zh) | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 | |
CN110088101A (zh) | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 | |
JP2021512092A (ja) | Prc2阻害剤 | |
CN111377907B (zh) | 一种多取代苯氨基嘧啶衍生物及其制备方法和用途 | |
CN110041316A (zh) | Tam家族激酶/和csf1r激酶抑制剂及其用途 | |
CN110072865A (zh) | 吡咯并芳杂环类化合物及其制备方法和医药用途 | |
WO2015187088A1 (en) | Mth1 inhibitors for treatment of cancer | |
JP2022530866A (ja) | Prc2阻害剤としてのナフチリジン誘導体 | |
WO2022166860A1 (zh) | Pim激酶抑制剂 | |
CN112313207A (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
CN115785154A (zh) | 杂芳环化合物及其医药用途 | |
CN116997545A (zh) | 杂环取代的甲酮类衍生物、其组合物及医药上的用途 | |
CN113880833A (zh) | 联苯多环类衍生物抑制剂、其制备方法和应用 | |
WO2022253081A1 (zh) | 氧化膦衍生物及其制备方法和应用 | |
CN113754685B (zh) | 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |